The Effectiveness of Phytotherapy in the Treatment of SARS-COV2 (COVID-19)
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Number of patients
研究概览
简要总结
Quercetin is one of the flavonoids. Quercetin as well as rutin are recognized to be among the most active of the flavonoids. It is to quercetin that several medicinal plants, including ginkgo and St. John's Wort, owe part of their therapeutic effects. Often combined with vitamin C in supplements, it improves absorption by the body and delays its elimination.
Quercetin is extracted from a variety of plant sources, including the onion peel and seeds and pods of Dimorphandra mollis, a tree in the legume family native to South America.
At present, there is no scientific data to demonstrate the effectiveness of herbal medicine, regardless of the plant, to prevent or treat COVID-19. On the other hand, some plant-based food supplements have anti-inflammatory or immunomodulatory properties that may disrupt inflammatory defense mechanisms useful in fighting infections, and in particular against COVID-19.
详细描述
Type of study: a randomized, double-blind study using the Quercetine in the treatment of patients with SARS COV2 (covid-19) Quercetin is extracted from a variety of plant sources, including the onion peel and the seeds and pods of Dimorphandra mollis, a legume tree native to South America.
Although we are far from knowing everything about quercetin, its antioxidant, anti-inflammatory, and antihistamine (antiallergic) properties have been observed in numerous in vitro and animal studies.
History on quercetin In 1937, Albert Szent-Gyorgyi received a Nobel Prize for discovering vitamin C and flavonoids, as well as for exploring their biochemical properties. Originally, he gave the flavonoids the name "vitamin P" because of their effectiveness in reducing the permeability of blood vessels. This name was abandoned when it was realized that these substances were not really vitamins.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Care Provider)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •all patients attending the emergency department for influenza-like illness.
- •Being over 18 years old
排除标准
- •Any patient requiring admission
- •Non-consenting patients
研究组 & 干预措施
Quercetix group
Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal.
干预措施: Quercetin (Drug)
Placebo Group
Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal.
干预措施: Quercetin (Drug)
结局指标
主要结局
Number of patients
时间窗: 10 DAYS
Number of patients attending the emergency room
次要结局
- disappearance of symptoms(10 days)
- adverse reaction(10 days)
研究者
Riadh Boukef
Professor
Hôpital Universitaire Sahloul